Skip to main content
. Author manuscript; available in PMC: 2015 Sep 2.
Published in final edited form as: JAMA Oncol. 2015 May 1;1(2):238–244. doi: 10.1001/jamaoncol.2015.34

Figure 2. Whole-Exome Sequencing of the Pretreatment Tumor.

Figure 2

A, There is no evidence of EGFR amplification. B, Heuristic analysis of the somatic mutations, short insertions and deletions, and copy number alterations across the exome identifies 4 mutations for additional evaluation: TP53, ARID1A, ABL2, and MAPK1. The horizontal line denotes the separation between nonsynonymous and synonymous variants, and COSMIC indicates the Catalogue of Somatic Mutations in Cancer database. C, The location of E322 is near the terminal end of the MAPK1 protein, in the common docking domain. Numbers indicate the color-coded regions of the protein. D, The E322 locus is highly conserved across species.